Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

The application of artificial intelligence (AI) has been considered a revolutionary change in
drug discovery and development. In 2020, the AlphaFold computer program predicted …

The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

Suppression of antitumor immune responses is one of the main mechanisms by which tumor
cells escape from destruction by the immune system. Myeloid-derived suppressor cells …

Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …

Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic
hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues …

Immune checkpoint inhibitors (ICI) used for cancer immunotherapy were shown to boost the
existing anti-tumor immune response by preventing the inhibition of T cells by tumor cells …

Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually
diagnosed in advanced stages due to late symptom manifestation with very limited …

Liver cancer has the fourth highest mortality rate of all cancers worldwide, with
hepatocellular carcinoma (HCC) being the most prevalent subtype. Despite great advances …